Galderma stock trades at EUR 179.45 with P/ E 49.2

Published on 10/12/2026 at 13:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Galderma stock costs EUR 179.45 on October 12, 2026, while P/E stands at 49.2. Q3 results are scheduled for October 22, 2026.

Key points in brief

Galderma stock traded at EUR 179.45 at Lang & Schwarz on October 12, 2026 at 12:59 p.m. CEST.
The stock's P/E ratio was 49.2, with market capitalization at CHF 39.0 billion.
Galderma's Q3 2026 trading update is scheduled for October 22, 2026.
The average analyst target was USD 217.18, according to Eulerpool data for October 2026.

Galderma, CH1335392721, Illustration mit AI erstellt.

Galderma stock (ISIN CH1335392721) was trading at EUR 179.45 at Lang & Schwarz on October 12, 2026 at 12:59 p.m. CEST, while its P/E ratio stood at 49.2. The next scheduled company milestone is the Q3 2026 trading update on October 22, 2026, according to Galderma.

Price meets a high valuation

The Lang & Schwarz euro quote gives German investors a direct market reference for Galderma, while the Swiss listing provides the home-market context. On SIX, the stock last traded at CHF 167.10 on October 12, 2026 at 12:39 p.m. CEST.

Galderma's 52-week range was CHF 134.70 to CHF 188.25 on October 12, 2026. The current SIX price therefore stood within the established annual range, while market capitalization reached CHF 39.0 billion and trading volume was 58,558 shares against an average volume of 547,034 shares.

Analyst targets set a higher bar

Eulerpool listed an average analyst price target of USD 217.18 for Galderma in October 2026, alongside 15 Buy, 4 Hold and 0 Sell ratings. Its median target was USD 227.71, while the last price shown by that source was USD 195.69, according to Eulerpool.

Simply Wall St reported a consensus target of CHF 197.55 against a current share price of CHF 165.85 on October 10, 2026. The same analysis put the forward 2029 P/E at 31.6, compared with 53.6 on its current profit base, and identified execution on Nemluvio and Relfydess as a central operating consideration, according to Simply Wall St.

Comparison with peers

Galderma: P/E 49.2, market capitalization CHF 39.0 billion

Novartis (SIX, CHF): listed peer

Sandoz (SIX, CHF): listed peer

October results date approaches

The October 22, 2026 trading update gives the next concrete date for investors tracking sales execution and product adoption. The scheduled update follows Galderma's first-half 2026 results and places the next company disclosure within the current reporting cycle.

Galderma stock at Lang & Schwarz

Galderma stock was trading at EUR 179.45 at Lang & Schwarz on October 12, 2026 at 12:59 p.m. CEST. The P/E ratio was 49.2 and market capitalization stood at CHF 39.0 billion.

The further course of trading is shown by the continuously updated real-time quote of Galderma stock.